Acute metabolic actions of the major polyphenols in chamomile: an in vitro mechanistic study on their potential to attenuate postprandial hyperglycaemia by Villa-Rodriguez, JA et al.
1SCIentIfIC REPORTS |  (2018) 8:5471  | DOI:10.1038/s41598-018-23736-1
www.nature.com/scientificreports
Acute metabolic actions of the 
major polyphenols in chamomile: 
an in vitro mechanistic study 
on their potential to attenuate 
postprandial hyperglycaemia
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Lauren Ford2,3, Richard S. Blackburn  3, Christopher Rayner  2 & Gary Williamson  1
Transient hyperglycaemia is a risk factor for type 2 diabetes and endothelial dysfunction, especially 
in subjects with impaired glucose tolerance. Nutritional interventions and strategies for controlling 
postprandial overshoot of blood sugars are considered key in preventing progress to the disease state. 
We have identified apigenin-7-O-glucoside, apigenin, and (Z) and (E)−2-hydroxy-4-methoxycinnamic 
acid glucosides as the active (poly)phenols in Chamomile (Matricaria recutita) able to modulate 
carbohydrate digestion and absorption in vitro as assessed by inhibition of α-amylase and maltase 
activities. The latter two compounds previously mistakenly identified as ferulic acid hexosides were 
purified and characterised and studied for their contribution to the overall bioactivity of chamomile. 
Molecular docking studies revealed that apigenin and cinnamic acids present totally different poses 
in the active site of human α-amylase. In differentiated Caco-2/TC7 cell monolayers, apigenin-7-O-
glucoside and apigenin strongly inhibited D-[U-14C]-glucose and D-[U-14C]-sucrose transport, and 
less effectively D-[U-14C]-fructose transport. Inhibition of D-[U-14C]-glucose transport by apigenin 
was stronger under Na+-depleted conditions, suggesting interaction with the GLUT2 transporter. 
Competitive binding studies with molecular probes indicate apigenin interacts primarily at the 
exofacial-binding site of GLUT2. Taken together, the individual components of Chamomile are 
promising agents for regulating carbohydrate digestion and sugar absorption at the site of the 
gastrointestinal tract.
Excess consumption of carbohydrates and sugars can lead to hyperglycaemia, endothelial dysfunction and insu-
lin resistance, increasing the risk of developing of type 2 diabetes and cardiovascular diseases. The modulation 
of carbohydrate digestion in the intestine by the non-absorbed drug acarbose reduced the risk of type 2 diabetes 
and cardiovascular events by 25 and 49% respectively in a population with impaired glucose tolerant according 
to The Study To Prevent Non-Insulin dependent Diabetes Mellitus trial1,2, indicating the clinical relevance of this 
approach. Gastrointestinal side-effects of acarbose have resulted in poor patient compliance and adherence to 
the treatment, highlighting the need for the identification of new molecules which could restrict post-prandial 
burden. To this end, we previously screened several plant extracts and identified German chamomile (Matricaria 
recutita) (ChE) as very effective at attenuating carbohydrate digestion and sugar absorption in vitro3.
Chamomile is used as an herbal tea all over the world, and recognition of its medicinal properties is exem-
plified by its listing as an official drug in the pharmacopoeias of 26 countries including the UK4. It can poten-
tially relieve the metabolic overload effects of high sugar diets such as glucose and fructose by attenuating their 
absorption through the inhibition of carbohydrate-digestive enzymes and apically-located transporters3; this 
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mechanism may explain some of the positive effects observed by chamomile in experimental diabetes5,6 and type 
2 diabetics7,8.
Chamomile contains many different phytochemicals, mainly (poly)phenols, a class of small molecules with 
several bioactivities9,10. (Poly)phenol content varies depending on growth conditions and extraction methods and 
this can have a pronounced impact on biological activities. Therefore, a first and essential step is to identify the 
specific active constituents responsible for the bioactivity. In another study where authors attempted to identify 
inhibitors of digestive enzymes in chamomile a convincing single candidate was not described5. Furthermore, 
individual components of chamomile have been previously reported to have a beneficial inhibitory effect on 
monosaccharide transport; however, the contribution of each on the overall exerted effect by ChE is not known. 
Here we report the inhibitory activity of the main (poly)phenol constituents of ChE on the different steps of 
carbohydrate digestion and absorption, while for the first time we have fully confirmed and characterized two 
previously misidentified glycosylated hydroxycinnamic acids present in ChE at high concentrations and assessed 
their contribution to the potential of ChE to counteract hyperglycaemia.
Results
Analytical and semi-preparative HPLC-DAD analysis of chamomile. Initial detection of target 
(poly)phenols in ChE was based on our previous report3 where we identified by mass spectrometry apigenin, 
apigenin-7-O-glucoside and two compounds with corresponding [M-H]- ion masses at m/z 355 and 711 (com-
pounds 1 and 2) as the most abundant constituents. In this study, apigenin-7-O-glucoside (compound 3) and 
apigenin (compound 4) (Fig. 1A; Table 1) were detected based on the comparison of their retention time with 
those of authentic standards. The UV absorption spectra of compounds 1 and 2 (Fig. 1B) were characteristic of 
methoxycinnamic acid derivatives. The compounds were separated, isolated and concentrated by semi-prepara-
tive column chromatography (supplementary S1) yielding enough material to perform in vitro experiments. The 
purity of the collected fractions, pooled after freeze-drying, was >80% for compound 1 and >99% for compound 
2 as assessed by liquid chromatography-mass spectrometry (LC-MS) based on the total ion count chromatograms 
(TIC).
Chemical characterisation of the hydroxycinnamic acid derivatives. The identities of the hydrox-
ycinnamic acid derivatives were assigned based on HPLC-DAD/QTOFMS, 1H and 13C NMR, NOESY and 
chemical synthesis. The full-scan TOF spectra of both compounds showed prominent ions at m/z 355.1035 and 
Figure 1. HPLC-DAD chromatogram of ChE extract. Targeted compounds are referred to according to the 
retention time sequence. For retention time, refer to Table 1.
Compound Rt (min) Concentration (µM) LOD (µM) LOQ (µM)
1* 8.7 257.0 ± 2.2 0.42 1.32
2 10.5 200.9 ± 2.0 0.46 1.43
3 12.1 148.7 ± 2.0 2.62 8.18
4 15.8 12.22 ± 0.08 2.48 7.75
Table 1. Identification and quantification of targeted (poly)phenols in ChE. *The quantification was conducted 
with the isolated standard with a purity ≥80%. An isomerisation reaction took place where (Z)-MCAG 
(compound 1) changed to the most thermodynamically stable form (E)-MCAG (compound 2) which accounts 
for the impurity detected. The identification of compound 1 and 2 is described in section 3.2.
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711.2136, which were assigned as [M-H]- and [2M-H]- respectively (Table 2). This assignment was further con-
firmed by the appearance of the [M+Cl]- ion at m/z 391.0801 in the spectrum of compound 2. The (neutral) 
elemental formula of the two hydroxycinnamic acid derivatives was established as C16H20O9. Both compounds 
showed identical fragment ions in the Q/TOF product ion spectra at m/z 193.0506 [M-hexosyl-H]- and 149.0608 
[M-hexosyl-CO2]-. This result excluded the possibility that either of the compounds is a dimer of ferulic acid 
hexoside as suggested by Guimarães et al.11 based on the predominant ion at m/z 711 for compound 2. Covalently 
bound ‘dimeric ferulic acids’ are well characterised compounds, which act like polysaccharide cross-linking 
agents in cell walls12,13, and therefore their (di)glycoside structures can also be theoretically expected in plant 
Compound [M-H]- MS2
Elemental 
formula
Measured 
m/z Exact mass
Error 
(ppm)
1
355 [M-hexosyl-CO2]- C9H9O2 149.0599 149.0608 −6.04
355 [M-hexosyl]- C10H9O4 193.0496 193.0506 −5.18
355 [M-H]- C16H19O9 355.1017 355.1035 −5.07
711 [M-hexosyl]- C10H9O4 193.0497 193.0506 −4.66
711 [M-H]- C16H19O9 355.1029 355.1035 −1.69
711 [2M-H]- C32H39O18 711.2152 711.2136 2.25
2
355 [M-hexosyl-CO2]- C9H9O2 149.0599 149.0608 −6.04
355 [M-hexosyl]- C10H9O4 193.0493 193.0506 −6.73
355 [M-H]- C16H19O9 355.1034 355.1035 −0.28
711 [M-hexosyl]- C10H9O4 193.0494 193.0506 −6.22
711 [M-H]- C16H19O9 355.1022 355.1035 −3.66
711 [2M-H]- C32H39O18 711.2114 711.2136 −3.09
Table 2. Q/TOF-MS/MS of isolated compounds from ChE.
Figure 2. Analysis of compound 2 after acid hydrolysis. (A) HPLC-DAD chromatogram of the hydrolysed 
fraction and comparison of the released compounds with ferulic acid standard. (B) UV-Vis spectra of ferulic 
acid standard and compounds resulting from acid hydrolysis. (C) Comparison of the resulting compounds after 
acid hydrolysis with standards of (E)-MCA and 7-methoxycoumarin. (D) HPLC-DAD chromatograms of PMP 
derivatives of standard monosaccharides: 1-D-mannose; 2-D-glucose; 3-D-galactose; 4-D-xylose.
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extracts. However, the predicted ion formula [C32H37O18]- would result in a monoisotopic ion mass of m/z 
709.1985 in negative ion mode. Confirmatory fragmentation of the m/z 711.2136 was performed by Q/TOF 
that provided fragments only at m/z 355 and 193, lending further support to our original assumption that the 
elemental formula of the two hydroxycinnamic acid derivatives is C16H20O9. Further analysis was performed to 
conclusively rule out the isomeric structures of ferulic acid hexosides previously suggested.11,14,15
Acid hydrolysis of compound 2 did not result in the release of ferulic acid as would be expected if the com-
pounds were ferulic acid hexosides (Fig. 2A–C). However, a compound with m/z(-) 193 (supplementary S2) with 
UV spectra characteristic of hydroxycinnamates was detected at 13.4 min (Fig. 2C). We also observed a peak at 
15.3 min with a UV spectra distinctive of coumarins16, later confirmed as 7-methoxycoumarin by comparison 
with the authentic standard (Fig. 2C). The presence of 7-methoxycoumarin was indicative of the release of a 
O-hydroxycinnamate which, under the acidic conditions16 employed for hydrolysis, underwent intramolecular 
cyclization.
The 1H-NMR data displayed spectroscopic signals characteristic of a free carboxylic group, which was 
identified from detection of the signal at δ 12.00. The presence of a (Z) and (E)-alkene group in the structure 
of compound 1 and 2 were identified from the signals at δ 7.19 and 5.78 (J = 12.7 Hz), and δH 7.82 and 6.39 
(J = 16.2 Hz), respectively. The spectrum also indicated the presence of three aromatic protons in the ABD sub-
stitution pattern characteristic of the coupling constants of J = 8.5–8.6 (ortho) and J = 2.4–2.5 (meta)17. Acid 
hydrolysis of compounds 1 and 2 resulted in the release of D-glucose (Fig. 2D). The 1H chemical shift in the range 
4.85 (Z-isomer) and 4.98 (E-isomer) with coupling constants of J = 7.5 Hz from the anomeric protons indicate a 
β-glycosidic linkage and the location of the D-glucose moiety was assigned at the aromatic ring by the observed 
NOE enhancements (Fig. 3A). The NOE enhancements gave an indication of the position of the other functional 
groups around the ring. The 13C NMR data showed 16 carbon resonances for the phenolic moiety in isolated 
compound 2, suggesting that the compounds are (Z) and (E)−2-β-D-glucopyranosyloxy-4-methoxycinnamic 
acid (Z and-E-MCAG). Further confirmation of the identity of the cinnamate moiety was obtained by chemical 
synthesis, and comparison with the released aglycone after acid hydrolysis (Fig. 2C).
Inhibition of human α-amylase and rat α-glucosidase activities by ChE (poly)phenols. In vitro 
assays. As we previously found that ChE could inhibit human α-amylase and rat maltase activity3 and further 
confirmed in this study (Fig. 4A), we tested the inhibitory activity of its individual component (poly)phenols. 
Apigenin and its precursor apigenin 7-O-glucoside exhibited the most potent inhibition against α-amylase as 
evidenced by the dose-dependent response (Fig. 4B). (Z)-MCAG and (E)-MCAG were also active, although they 
showed only modest inhibition with maximum values ~25 and ~20% respectively (p < 0.05) (Fig. 4B). When 
the four (poly)phenols were combined at concentrations equivalent to those quantified in the ChE preparation, 
Figure 3. (A) Chemical structures of isolated compounds (1 & 2). Key NOESY correlations for compound 2 
are indicated with arrows and percentage enhancements. (B) Scheme showing the synthetic aglycone and the 
corresponding coumarin ring closure.
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Figure 4. Inhibition of human α-amylase activity by ChE and component (poly)phenols. (A) Dose-dependent 
inhibition of ChE. IC50 for acarbose was obtained and used as positive control. (B) Dose-dependent inhibition 
by individual (poly)phenols. Inhibition is expressed as % compared to control incubations (no inhibitor; 
normalised to 100%). (C) Combined and individual inhibition of (poly)phenols at concentrations equivalent 
to those present in the ChE: (Z)-MCAG, 257 µM; (E)-MCAG, 200 µM; apigenin 7-O-glucoside (A7G), 148 µM; 
apigenin, 12 µM. (D,E) Dixon plot showing the kinetic analysis of apigenin and A7G against α-amylase. The 
intercept value represents –Ki. Data is expressed as mean ± SEM of three independent experiments with at 
least three technical replicates. When not visible, the error bars are smaller than the data point(s). (F–J) Charge 
surface representation (in blue and red) of α-amylase binding cavity with respective ligands displayed in stick 
format (in purple); (F) (Z)-MCAG, (G), (E)-MCAG, (I) apigenin and (J) A7G. Next to each 3D complex are 
schematic representations of the 2D interactions between each ligand and amino acid residues including the 
length of each interaction (in Å) as displayed by Discovery Studio software. (K) Close-up 3D view illustrating 
the H-bond and π-π stacking interactions of apigenin adjacent to amylase active site residues.
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apigenin 7-O-glucoside showed the highest contribution (p < 0.05) (Fig. 4C). Moreover, their combination 
resulted in a ~20% increase of the inhibitory activity when compared to ChE.
While ChE weakly inhibited rat intestinal maltase, no inhibitory effect was observed on rat sucrase and iso-
maltase (Fig. 5A); even at the highest tested concentration only a modest ~33% (p < 0.05) inhibition was evident. 
When individual constituents were tested at concentrations equivalent to those present in ChE and higher, rat 
maltase was similarly only weakly inhibited by the individual (poly)phenols and apigenin 7-O-glucoside was the 
principal contributor (p < 0.05) (Fig. 5B,C). Nevertheless, a dose response was obtained for inhibition with ChE 
Figure 5. Inhibition of rat maltase activity by ChE and (poly)phenols. (A) Dose-dependent inhibition of ChE. 
IC50 for acarbose was obtained and used as positive control. (B) Dose-dependent inhibition of individual (poly)
phenols. (C) Combined and individual inhibition effect of (poly)phenols at concentrations equivalent to those 
present in the ChE: (Z)-MCAG, 257 µM; (E)-MCAG, 200 µM; apigenin 7-O-glucoside (A7G), 148 µM; apigenin, 
12 µM. Data is expressed as mean ± SEM of three independent experiments with at least three technical replicates.
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Figure 6. Monosaccharide transport across Caco-2/TC7 cells monolayers and inhibition by ChE and its 
major (poly)phenol constituents. (A-1) Transport D-[U-14C]-glucose and D-[U-14C]-sucrose in the absence of 
inhibitors. (A-2) Dose-dependent inhibition of D-[U-14C]-glucose and D-[U-14C]-sucrose transport by ChE. 
(A-3) Inhibition of D-[U-14C]-fructose by ChE at a single concentration (1 mg/mL). For D-[U-14C]-glucose and 
D-[U-14C]-sucrose transport the IC50 values were calculated as 0.24 ± 0.02 and 0.91 ± 0.06 mg/mL respectively. 
For D-[U-14C]-fructose, the maximum inhibition at the concentration tested was 28%. (B-1) Concentration-
dependent inhibition of D-[U-14C]-glucose and D-[U-14C]-sucrose by apigenin 7-O-glucoside (A7G). (B-2) 
Inhibition of D-[U-14C]-glucose and D-[U-14C]-sucrose by apigenin at a single concentration (50 µM). (B-3) 
Inhibition of D-[U-14C]-fructose by A7G and apigenin at a single concentration; A7G (200 µM), apigenin 
(50 µM). (B-4) Inhibition of monosaccharide transport by ChE and combined inhibition of apigenin and A7G; 
apigenin, 12 µM; A7G, 148 µM. (C-1) Concentration-dependent inhibition of ChE under Na+-free conditions, 
IC50 = 0.138 ± 0.018 mg/mL. (C-2) Concentration-dependent inhibition of apigenin and A7G under Na+-free 
www.nature.com/scientificreports/
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and the four individual compounds. Although apigenin was found to be the most potent inhibitor of the four 
constituent (poly)phenols, its limited solubility prohibited testing at concentrations >50 µM (Fig. 5B). None of 
the individual (poly)phenols or their combination achieved 50% inhibition. (E)-MCAG was resistant to diges-
tive hydrolytic enzymes, indicating that 2-(E)-MCA would not be produced in significant amounts in the small 
intestine, and therefore 2-(E)-MCA was not assessed for inhibition of carbohydrate-digesting enzymes (supple-
mentary S3).
Molecular docking studies. Molecular docking was performed to investigate the structural basis of the observed 
inhibition on human α-amylase by individual (poly)phenols. Based on the strong inhibition observed for api-
genin, three important features were identified: (1) the formation of H-bonds between the OH group of the B 
ring and the catalytic residue Asp197, (b) the formation π-π stacking interactions with Trp59 and Tyr62 and (c) 
the stacking towards the binding subsites −1 and −2. As shown in supplementary S4, these observations were 
extended to other strong (poly)phenol inhibitors of human α-amylase (arbitrarily defined as molecules with IC50 
<100 µM) including EGCG, quercetin and luteolin18. Apigenin 7-O-glucoside is able to form π-π stacking inter-
actions with Trp59 and Tyr62, however it does not form the H-bond with the catalytic residue Asp197 resulting in a 
~10 fold lower inhibition in agreement with the in vitro results (Fig. 4J).
(Z) and (E)-MCAG bind in a completely different pose (Fig. 4F,G) and are able to form H-bonds with the 
catalytic residues, but, unlike apigenin, the H-bonds are formed mainly with the OH groups of the glucose moiety 
and would be possibly weaker judging by the distance of H-bonds formed. In the case of (Z)-MCAG, an H-bond 
is formed between the 6-OH group of the glucose unit with Asp197 while (E)-MCAG presents a more complex 
interaction. In (E)-MCAG, 2 covalent bonds are formed between the carbon at position 2 and Asp197 (indicated as 
carbon-hydrogen bond in Fig. 4). Furthermore, H-bond interactions occur between the 6-OH group and Glu233 
and Asp300 while an additional H-bond is formed between the Glu233 and the OH-present in the carboxylic group 
of the phenolic skeleton. These additional interactions would explain the slightly higher inhibition observed by 
the (E)-isomer (Fig. 4C) in vitro, and could perhaps account for its stability in the binding pocket given the lack 
of π-π stacking interactions.
Inhibition of glucose, sucrose and fructose transport by ChE (poly)phenols. Caco-2/TC7 cells 
transported 0.08 mmol of D-[U-14C]-glucose from the apical to the basolateral compartment across the cell mon-
olayers in the presence of Na+, where the sugar transporter Na+/glucose co-transporter 1 (SGLT1) is active, 
in addition to the facilitated transporters GLUT2 and GLUT5 (Fig. 6A-1). D-[U-14C]-sucrose must first be 
hydrolysed by brush border sucrase and the resulting products, fructose and glucose, are transported into and 
across the cells. ChE dose-dependently inhibited D-[U-14C]-glucose, D-[U-14C]-sucrose (Fig. 6A-2) and D-[U-
14C]-fructose transport (Fig. 6A-3).
In order to elucidate which (poly)phenols in ChE were responsible for the effect, each was tested separately 
on D-[U-14C]-monosaccharide transport across Caco-2/TC7 cell monolayers. Among individual (poly)phenols, 
apigenin 7-O-glucoside was a very effective inhibitor of D-[U-14C]-glucose and D-[U-14C]-sucrose transport, 
and IC50 values were obtained (Fig. 6B-1). Although an IC50 value could not be obtained for apigenin at the 
highest soluble concentration tested (Fig. 6B-2), it can be deduced that it is a more potent inhibitor based on the 
substantial 3-fold higher effect when compared with apigenin 7-O-glucoside at equivalent concentrations. Both 
(Z) and (E)-MCAG had no effect on D-[U-14C]-glucose, D-[U-14C]-sucrose or D-[U-14C]-fructose transport 
(data not shown). The combination of apigenin and apigenin 7-O-glucoside when tested at concentrations equiv-
alent to those quantified in the extract, accounted for ~62, 80 and 89% of the total transport inhibition of D-[U-
14C]-glucose, D-[U-14C]-sucrose and D-[U-14C]-fructose, respectively, exhibited by ChE (Fig. 6B-4).
To dissect the mechanism of inhibition of glucose transport, we conducted D-[U-14C]-glucose transport 
experiments under Na+-free conditions where only GLUT2, and not SGLT1, is active. An apparent increase 
(~50%) in the inhibitory activity was observed for ChE (p < 0.05), apigenin 7-O-glucoside and apigenin as 
evidenced by the decrease in the inhibition constants, suggesting that the main inhibitory effect is on GLUT2 
(Fig. 6C-1 and 2). When tested in combination under Na+-free conditions, apigenin 7-O-glucoside and apigenin 
(Fig. 6C-3) were responsible for ~80% of the inhibitory activity observed by the whole ChE (p < 0.05) (Fig. 6C-4).
Since the main inhibition we found was on GLUT2, we investigated the binding affinities of apigenin and 
apigenin 7-O-glucoside. Immunostaining of GLUT2 showed that GLUT2 protein was present on both apical 
and basolateral sides of differentiated Caco-2/TC7 cells (Fig. 7A). This was also confirmed by functional assays 
where the rate of D-[U-14C]-glucose transport under Na+-free conditions was the same from apical to basolat-
eral compartments and vice versa (Fig. 7B). Inhibition constants for the exofacial glucose transporter inhibitor 
4,6-O-ethylidene glucose and the endofacial glucose transporter inhibitor cytochalasin B on basolateral to apical 
D-[U-14C]-glucose transport were compared to those for apigenin and apigenin 7-O-glucoside (Fig. 7C–E). The 
results suggest that the two (poly)phenols bind at the exofacial side of the protein, since a 3-fold lower inhibition 
was observed when the D-[U-14C]-glucose transport was assessed from basolateral to apical side, which was also 
conditions. (C-3) Chemical structures of apigenin and A7G and their respective IC50 values under Na+-free 
conditions. (D) Combined inhibition of apigenin and A7G under Na+-free conditions; apigenin, 12 µM; A7G, 
148 µM. Each data point represents the mean ± SEM of three independent experiments with six technical 
replicates. Results are expressed as % compared to the transported sugars in control incubations (no inhibitor; 
normalised to 100%). When not visible, the error bars are smaller than the data point. In Fig (A2), (B1), (C1 
and C2) statistical difference is indicated against the incremental concentrations of each inhibitor. *p < 0.05, 
**p < 0.05.
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Figure 7. Characterisation of the binding site of apigenin and apigenin 7-O-glucoside (A7G) on GLUT2. 
Transport experiments were conducted under Na+-free conditions. (A) Immunofluorescence detection 
of GLUT2 in differentiated Caco-2/TC7 cell monolayers. Row 1 shows control cell layer incubated with 
4–6-diamidino-2-phenylindole (DAPI) and Cy3-conjugated donkey anti-rabbit secondary antibody only. 
Cells in rows 2–4 were incubated with DAPI, membrane marker wheat germ agglutinin (WGA), GLUT2 
primary antibody and Cy3-conjugated donkey anti-rabbit secondary antibody. GLUT2 is shown in red, 
appearing orange when co-localising with WGA shown in green. Nuclei are stained with DAPI (blue). Scale 
bars (10 µm) are shown in the lower left corner of DAPI images. Scale bar applies to all imagesin the row. 
Images are representative examples of three independent immunostaining experiments. (B) Asymmetric 
D-[U-14C]-glucose transport without inhibitor. (C) Asymmetric D-[U-14C]-glucose transport in the presence 
of cytochalasin B and inhibition constants. (D) Asymmetric D-[U-14C]-glucose transport in the presence of 
4,6-ethylidene glucose and inhibition constants. (E) Inhibition of asymmetric D-[U-14C]-glucose transport 
www.nature.com/scientificreports/
1 0SCIentIfIC REPORTS |  (2018) 8:5471  | DOI:10.1038/s41598-018-23736-1
observed for 4,6-O-ethylidene glucose. This comparison is made assuming that the position of GLUT2 is the same 
when facing the apical and the intracellular space, which seems to hold based on the rate of D-[U-14C]-glucose 
transport across the monolayers in both directions.
Caco-2/TC7 cells do not convert apigenin 7-O-glucoside to apigenin. Glycosylated (poly)phenols 
can be hydrolysed by luminal β-glucosidase enzymes, such as lactase phlorizin hydrolase19,20, present in the brush 
border of the enterocytes, resulting in the release of the aglycone. Therefore, we explored the possibility whether 
the inhibition observed by apigenin-7-O-glucoside was due to the presence of apigenin after enzymic hydrolysis. 
Caco-2/TC7 cells were incubated with 150 µM apigenin 7-O-glucoside for 25 and 60 min. In vitro conversion of 
apigenin 7-O-glucoside to apigenin in Caco2/TC7 cells was negligible (Supplementary S5) confirming that api-
genin 7-O-glucoside can interact directly with GLUT2 transporter protein.
Discussion
Repeated high postprandial glucose spikes and fructose related metabolic burden have been proposed as inde-
pendent risk factors for developing insulin resistance and progression to type 2 diabetes21–24. Delaying the absorp-
tion of sugars in the intestine is considered a clinically relevant approach for reducing type 2 diabetes risk22,23. The 
present study was designed to identify the (poly)phenols involved in the inhibition of carbohydrate digestion and 
absorption previously demonstrated by ChE3 and further explore their mechanism of action.
In the work presented here we have provided conclusive evidence of the presence of (Z) and 
(E)−2-β-D-glucopyranosyloxy-4-methoxycinnamic acids in ChE, in agreement with the tentative identification 
of Weber et al.17. These compounds were previously misidentified as ferulic acid hexosides and ‘dimer’ forms by 
several authors11,14,15,25. When they were individually tested, they showed modest inhibitory activity on human 
α-amylase; however, when assessed in combination with apigenin and apigenin 7-O-glucoside, it was evident that 
they significantly contribute to the overall bioactivity of ChE.
In vitro and in silico studies revealed that apigenin and apigenin 7-O-glucoside are primarily responsible for 
the inhibition of human α-amylase by ChE, and this arises in part from their ability to occupy the binding pocket 
and stack between subsite “−1 and −2” through π-π interactions. The side chain residue of Asp197 is believed to 
act as nucleophile during the catalytic reaction of α-amylase and its substitution dramatically decreased (106-fold) 
its catalytic activity26. Unlike apigenin 7-O-glucoside, apigenin showed additional interaction with Asp197 through 
an H-bond and this was reflected in a ~10-fold increase in its inhibitory activity. Thus, H-bonds between OH 
groups of the B ring and catalytic residues, and π-π stacking interactions appear to be requirements for an opti-
mal inhibition of human α-amylase by (poly)phenols acting via a competitive mechanism. Indeed, in a previous 
study, Lo Piparo et al.27 observed similar features; (poly)phenols showing IC50 <100 µM were anchored in the 
active site through π-π interactions with Trp59, and formed H-bonds with residues Asp197 and Glu233 through 
OH groups in the A and B rings. This mechanism is further supported by X-ray structural analyses of the (poly)
phenols myricetin and montbretin A with human pancreatic α-amylase28,29.
The final step of starch digestion is catalysed by α-glucosidases, maltase-glucoamylase and sucrase-isomaltase. 
Their combined catalytic activities hydrolyse linear and branched malto-oligosaccharides after the action of pan-
creatic α-amylase30 while sucrase-isomaltase additionally hydrolyses sucrose, producing glucose and fructose. 
Inhibition of α-glucosidases is complementary in strategies aiming at blunting blood sugar spikes stemming from 
consumption of readily absorbable sugars which increase the prospect of type 2 diabetes.31,32 Our results indicate 
only a modest inhibition of maltase-glucoamylase by the four (poly)phenols, even when tested in combination, 
consistent with the inhibition observed for ChE. In contrast, Kato et al.5 found a stronger inhibition of ChE 
against maltase-glucoamylase (IC50 = 2.6 mg/mL) and sucrase-isomaltase (IC50 = 0.9 mg/mL) using brush border 
membranes prepared from rat small intestine. The authors suggested that this effect was driven by the presence of 
esculetin (maltase IC50 = 534 μM; sucrase IC50 = 72 μM) and quercetin aglycone (maltase IC50 = 216 μM; sucrase 
IC50 = 71 μM). However, the phytochemical composition and content of the plant material used in the study was 
not reported. Data from other studies on chamomile composition indicate that these compounds, if present at 
all, are unlikely to be effective since they are several orders of magnitude below the concentrations necessary for 
inhibition11,33,34.
At low concentrations, the uptake of glucose and fructose relies on SGLT1 and the facilitated transporter 
GLUT5, respectively. However, after consumption of a meal high in sugars, glucose concentration may reach 
50–300 mM in the intestinal lumen prompting the facilitated GLUT2 transporter to translocate to the apical 
membrane. GLUT2 accounts for ~75 and ~60% of total glucose and fructose uptake respectively.35,36 Our data 
show that apigenin and apigenin 7-O-glucoside are potent and selective inhibitors of GLUT2 as these compounds 
account for up to ~80% of transport inhibition under Na+-depleted conditions. They bind at the exofacial site of 
the protein as demonstrated by comparing binding affinities with specific inhibitors of the intra- and extracellular 
cavities of the transport channel. In contrast, apigenin and apigenin 7-O-glucoside showed a modest inhibition 
by apigenin and A7G. Dotted line represents the inhibition values obtained at the maximum concentration 
tested when D-[U-14C]-glucose transport was assessed from apical (a) to basolateral (b) (data replotted from 
Fig. 6C-2). Data is expressed as mean ± SEM of three independent experiments with at least three technical 
replicates. In panel (B,C) results are expressed as % compared to the transported glucose in control incubations 
(no inhibitor; normalised to 100%). When not visible, the error bars are smaller than the data point. In panel 
(B) and (C), statistical difference is indicated against the incremental concentration of cytochalasin B and 
4,6-ethylidene glucose respectively. **p < 0.05.
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of fructose transport and only a small fraction of the transport of D-[U-14C]-fructose was inhibited following 
hydrolysis of D-[U-14C]-sucrose by brush-border α-glucosidase. However, a higher inhibition of fructose trans-
port in a physiological context can be expected since the apical expression of GLUT5 in the Caco-2 clone is com-
parable to the one noted in an adult small intestine37 and Caco-2/TC7 cell line presents a 2-fold increase in apical 
GLUT5 compared to Caco-2 cells3.
Like other (poly)phenols, apigenin and apigenin 7-O-glucoside are bioavailable in humans but are rapidly 
metabolised and excreted, while they are subject to extensive colonic catabolism38,39. Currently, there are no phar-
macokinetic data on (Z)- or (E)-MCAG but it is anticipated that they can reach the colon and are subject to 
catabolic reactions as observed for other hydroxycinnamic acids40, especially given that (E)-MCAG was not a 
substrate for rat intestinal enzymes. Based on information from other related compounds41,42, no harmful effects 
are predicted after dietary exposure of these (poly)phenols through consumption.
Several papers have reported that apigenin in various herbal and plant extracts can inhibit α-glucosidase 
activity. For example, apigenin-7-O-glucoside inhibited rat intestinal α-glucosidase activity, but the study used 
p-nitrophenyl-glucopyranoside, rather than the physiological substrate (maltose)43. Many studies have used yeast 
as a source of α-glucosidase activity, which has no relevance to the mammalian enzymes44. Hence apigenin did 
not inhibit yeast α-glucosidase action on the non-physiological substrate p-nitrophenyl-glucopyranoside in one 
report45, but did inhibit in other reports with an IC50 value of 22 μM in46 and of 25.5 μg/ml in47. In the lat-
ter report, apigenin-7-O-glucoside also inhibited with an IC50 value of 29.7 μg/ml47. Apigenin lowered GLUT1 
expression in a nude mouse model of laryngeal carcinoma48 and in prostate cancer cells49.
Based on our data, we propose that ChE, a natural source that combines (Z) and (E)-MCAG, apigenin and 
apigenin 7-O-glucoside, could pose a good alternative to modulate postprandial sugar excursions. Unlike the 
antidiabetic drug acarbose, the combination of these (poly)phenols can mildly attenuate carbohydrate digestion 
and sugar absorption, avoiding the gastrointestinal side effects of acarbose. Furthermore, apigenin and apigenin 
7-O-glucoside could be employed either alone or in combination with other inhibitors for an enhanced formula-
tion, for example in a population that has already developed a pathophysiological phenotype.
Materials and Methods
Preparation of ChE. The ChE used in this study and in enzymic in vitro assays has been previously fully 
described.3
Isolation of hydroxycinnamic acid derivatives by semi-preparative column chromatography. 
Two hydroxycinnamic acid derivatives detected based on previously published multiple reaction monitoring 
pairs by LC-MS were separated and isolated using an ÄKTA Purifier System (GE Healthcare Life Sciences, UK) 
equipped with an Gemini C6 phenyl column (250 × 10 mm I.D., 5 μm; Phenomenex, Cheshire, UK). The ChE 
extract (150 mg/mL) was loaded manually (1 mL) using a syringe through a sample loop of 1 mL and eluted 
using water containing 0.1% TFA (solvent A) and methanol (Solvent B) at a flow rate of 2.3 mL/min as follows: 
0–12.8 min linear gradient to 24% B; 12.8–25.6 min isocratic at 24% B; 25.6–111 min linear gradient to 100% B; 
111–123.8 min isocratic at 100%B, 123.8–125 min linear gradient to 5% B: 125–150.6 min isocratic at 5%B. The 
elution was followed at 320 nm and fractions containing the separated compounds (supplementary S1) were col-
lected and analysed for purity by LC-MS (supplementary S6). Multiple semi-preparative separation cycles were 
undertaken and the fractions for each peak combined, freeze-dried, and stored at −20 °C.
Chemical characterisation of hydroxycinnamic acid derivatives. HPLC/QTOFMS. Analysis of the 
purified hydroxycinnamic acid derivatives was carried out using an Agilent 1200 series HPLC system coupled to 
an Agilent 6530 Q/TOF mass spectrometer (Agilent Technologies, USA) equipped with a dual spray ESI source 
operating in negative mode. Followed by an isocratic separation with reversed phase HPLC, elemental formu-
lae of compounds were determined with the aid of MassHunter software based on high-resolution (>20,000 
FWHM) accurate mass (<5 ppm) data completed with evaluation of isotope abundance matching and isotope 
spacing. Data was obtained from full-scan TOF-only peak spectra acquired in the mass range of m/z 50–1100. 
Next, manually selected ion peaks of the TOF-only spectra were subjected to Q/TOFMS analysis and elemental 
formulae of fragments were determined based on accurate mass (<20 ppm) data obtained from product ion peak 
spectra.
Acid hydrolysis. An aliquot of the purified compound 2 (Fig. 1 and supplementary S1) was dissolved in HCl 
(2 M) to a concentration of 500 µM and subjected to hydrolysis for 2 h at 60 °C. The reaction mixture was con-
centrated to dryness under vacuum, reconstituted in water (1 mL) and analysed by HPLC-DAD on an Agilent 
1200 series system (Agilent Technologies, USA) equipped with a Kinetex C18 analytical column (150 × 2.1 mm 
I.D., 2.6 μm; Phenomenex, Cheshire, UK) maintained at 35 °C. 10 µL was injected and separated using a 41 min 
gradient of premixed 5% acetonitrile in water (5:95, v/v) (A) and premixed 5% water in acetonitrile (5:95, v/v) 
(B), both modified with 0.1% formic acid at 0.25 mL/min. The gradient started at 0% solvent B and increased to 
10% (5 min), 25% (10 min), 35% (20 min), 50% (25 min), and was held at a plateau up to 30 min. The gradient 
was increased 100% at 30.5 min and returned to 0% solvent B over 5.5 min before initial starting conditions were 
resumed for a 6 min column re-equilibration. Online detection was carried out at 320 nm.
A second aliquot was subjected to hydrolysis, concentrated to dryness and derivatised with 1-phenyl-
3-methyl-5-pyrazolone (PMP) as described elsewhere50,51. The derivatised sugar was analysed on HPLC-DAD 
equipped with a C18 analytical column (250 × 4.6 mm I.D., 5 µm, Phenomenex, Cheshire, UK) and UV detection 
at 250 nm. 10 µL of sample was eluted with 0.1 mM ammonium acetate buffer (pH 5.5)–acetonitrile (78:22, v/v) at 
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1 mL/min. The identification of the glycosyl component was done by comparing the retention time with those of 
authentic standards (D-mannose, D-glucose, D-galactose and D-xylose).
NMR. Purified samples were dissolved in d6 DMSO and transferred to 5 mm OD NMR tubes. All NMR data 
were recorded on a Bruker Avance 500 spectrometer (1H frequency 500.573 MHz, 13C frequency 125.878 MHz) 
temperature controlled at 299.3 K. Chemical shifts are expressed in ppm and are reported with reference to the 
residual solvent peak. Multiplicities are reported with coupling constants and are given to the nearest 0.1 Hz. 
Where needed, two-dimensional correlation spectroscopy (2D-COSY), heteronuclear single quantum coher-
ence spectroscopy (HSQC) and heteronuclear multiple bond correlation spectroscopy (HMBC) and nuclear 
Overhauser effect spectroscopy (NOESY) was performed.
(Z)-2-D-Glucopyranosyloxy-4-methoxycinnamic acid present as a mixture of E and Z in a 1:3 ratio, E 
peaks eliminated and Z peaks picked at: 1H NMR (501 MHz, DMSO-d6) δ 7.70 (d, J = 8.5 Hz, 1 H, H3), 7.19 
(d, J = 12.5 Hz, 1 H, cis-alkene, H2), 6.74 (d, J = 2.5 Hz, 1 H, H5), 6.56 (dd, J = 8.5, 2.5 Hz, 1 H, H4), 5.78 (d, 
J = 12.5 Hz, 1 H, cis-alkene, H1), 4.85 (d, J = 7.5 Hz, 1 H, anomeric proton, H8), 3.77 (s, 3 H, H6), 3.72 (broad 
d, J = 11.7 Hz, 1 H, H13), 3.47 (broad dd, J = 11.7, 6.0 Hz, 1 H, H13′), 3.38 (ddd, J = 10.0, 6.2, 1.6 Hz, 1 H, H12), 
3.34–3.29 (m, 2 H, H9 & H10)*, 3.16 (apparent t, J = 8.8 Hz, 1 H, H11) (. 13C NMR (126 MHz, DMSO-d6) δ 
167.7, 161.0, 160.7, 156.7, 136.32, 131.1, 117.53, 116.73, 101.11, 100.5, 77.24, 76.86, 73.27, 69.81, 60.72, 55.33. 
*Overlayed by strong signal from water. ESI-MS: m/z 355.1035 [M-H]-. The 1H assignments in the chemical 
structure are shown in supplementary S7-A.
Analysis of pure (E)−2-β-D-Glucopyranosyloxy-4-methoxycinnamic acid: 1H NMR (501 MHz, DMSO-d6) 
δ 12.00 (s, 1 H, H7), 7.82 (d, J = 16.2 Hz, 1 H, trans-alkene, H2), 7.62 (d, J = 8.7 Hz, 1 H, H3), 6.76 (d, J = 2.4 Hz, 
1 H, H5), 6.62 (dd, J = 8.6, 2.4 Hz, 1 H, H4), 6.39 (d, J = 16.2 Hz, 1 H, trans-alkene, H1), 5.16 (broad s, 1 H (OH)), 
4.98 (d, J = 7.5 Hz, 1 H, anomeric proton, H8), 4.89 (broad s, 2 H (OH)), 4.58 (broad s, 1 H, (OH)), 3.78 (s, 3 H, 
H6), 3.72 (broad d, J = 11.7 Hz, 1 H, H13), 3.47 (broad dd, J = 11.7, 6.0 Hz, 1 H, H13′), 3.38 (ddd, J = 10.0, 6.2, 
1.6 Hz, 1 H, H12), 3.34–3.29 (m, 2 H, H9 & H10)*, 3.16 (apparent t, J = 8.8 Hz, 1 H, H11). 13C NMR (126 MHz, 
DMSO-d6) δ 168.08, 162.08, 157.07, 138.76, 129.32, 116.73, 116.05, 108.03, 101.11, 100.02, 77.24, 76.86, 73.27, 
69.81, 60.72, 55.33. *Overlayed by strong signal from water. ESI-MS: m/z 355.1035 [M-H]-. The 1H assignments 
in the chemical structure are shown in supplementary S7-B. NOESY spectrum and key enhancements are shown 
in supplementary S8 and Fig. 3, respectively.
Synthesis of (E)−2-hydroxy-4-methoxycinnamic acid. 7-Methoxy coumarin (0.44 g, 2.5 mmol) was dissolved 
in an aqueous solution of 0.5 M NaOH (20 mL) and stirred for 4 h at room temperature. Aliquots were taken 
and showed full conversion to the trans carboxylate by NMR in D2O. The solution was then acidified with 1 M 
aqueous HCl and extracted with dichloromethane (3 × 10 mL). The solvent was then evaporated and eluted with 
ethyl acetate on a flash silica column. This yielded the (E)−2-hydroxy-4-methoxycinnamic acid (E-MCA) (32 mg, 
0.165 mmol, 6.6% yield). The low yield was due to the ring closing to reform the coumarin in acidic conditions. 
1H NMR (500 MHz, acetone) δ 9.25–9.21 (broad s, 1 H, H7), 7.95 (d, J = 16.1 Hz, 1 H, H2), 7.54 (d, J = 8.5 Hz, 1 H, 
H3), 6.40 (d, J = 2.2 Hz, 1 H, H5), 6.37 (dd, J = 2.2, 8.5 Hz, 1 H, H4) 6.33 (d, J = 16.1 Hz, 1 H, H1), 3.66 (s, 3 H, H6). 
The 1H assignments in the chemical structure are shown in supplementary S7-C.
The synthesised compound was analysed by HPLC-DAD as described in section 2.3. ESI-MS: m/z 193.06 
[M-H]- (supplementary S9).
Enzyme assays. The human α-amylase and rat α-glucosidase inhibition assays were performed under opti-
mised conditions as previously reported3,18,52. The ChE stock solution was dissolved in DMSO while the individ-
ual (poly)phenols were prepared in a water-EtOH solution (50:50, v/v). The maximum concentration of DMSO 
and EtOH in the assay was 2 and 1% respectively, which did not affect the activity of the enzyme as assessed in 
control incubations.
Molecular Modelling. We investigated the interactions of (poly)phenols with human α-amylase using the 
three-dimensional crystal structure 1MFV53. The α-amylase structure was prepared for docking by removing 
from the crystallographic structure water molecules and co-crystallised ligands. No constraints were introduced 
and the default parameters of the dock module of the CLC Drug Discovery 3.0.1 (CLC Bio-Qiagen) were used. 
Validation of the docking parameters was performed by docking the co-crystal modified structure of acarbose 
into the active site. A root mean square deviation of 1.36 Å was obtained between the original and the docked 
conformations (supplementary S10). The number of docking iterations for evaluation of the preferred binding 
pose was set at 500. Ten best docked poses per docking calculation were analysed based on their docking score 
and the top ranked pose for each ligand was selected for further analysis. Ligand-receptor interactions were 
visualised with CLC workbench and Discovery Studio (BIOVIA, Client version 2016).
Transport assay of monosaccharides in Caco-2/TC7 cells. Caco-2/TC7 cells were cultured and trans-
port experiments performed as fully described before3.
Immunofluorescence staining. Caco-2/TC7 cells were seeded at 7 × 104 cells/well on 12 well Millicell cell 
culture inserts (PET 0.4 mm pore size, Millipore) and maintained for 21–23 d at 37 °C (10% CO2). For staining, 
cells were fixed with 4% para-formaldehyde in PBS and incubated with wheat germ agglutinin (WGA, 1 mg/mL) 
for 10 min at 37 °C. Following permeabilisation with 0.1% Triton-X100 for 20 min at room temperature, cells 
were incubated with GLUT2 antibody (ab95256, Abcam, Cambridge, UK) at a dilution of 1:50 for 1 h, or without 
primary antibody for controls. After washing with PBS, cells were further incubated with Cy3-conjugated donkey 
anti-rabbit IgG at a 1:300 dilution. Cell layers were stained with 2 μg/mL 4′−6-diamidino-2-phenylindole (DAPI) 
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and mounted on microscope slides with ProLong Gold antifade reagent mounting medium (Carlsbad, USA) and 
imaged using a Zeiss LSM700 confocal microscope with a Plan-Apochromat 63 × oil immersion objective.
Estimation of conversion of apigenin 7-O-glucoside to apigenin by differentiated Caco-2/TC7 cells. 
Cells were seeded at 2.4 × 105 cells/well on 6-well plates (Corning, Appleton Woods, UK) and cultured for 21–23 
d at 37 °C as described above. Cells were exposed to 150 μM of apigenin 7-O-glucoside for 25 and 60 min. After 
the treatment the medium was collected and analysed by HPLC as detailed above.
Statistical analysis. Statistical analysis was performed by one-way ANOVA using the Number Cruncher 
Statistical System version 6.0 software (NCSS, LLC). Significant differences were assessed with Tukey-Kramer 
multiple comparison test (p < 0.05). Independent samples t-test was used to compare means of the contribu-
tion of apigenin 7-O-glucoside and apigenin to the total inhibition of sugar transport. Data are expressed as the 
mean ± standard error of mean (SEM).
Data availability statement. Data available on the Open Science Framework (ID: osf.io./fs32u).
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